Equity Overview
Price & Market Data
Price: $44.74
Daily Change: +$0.165 / 0.37%
Range: $41.67 - $44.74
Market Cap: $268,319,456
Volume: 1,303
Performance Metrics
1 Week: 11.39%
1 Month: 15.75%
3 Months: 6.37%
6 Months: 740.0%
1 Year: 1,257%
YTD: 100.5%
Company Details
Employees: 16
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.